

Scheme Update

Brisbane, Australia, 30 June 2022 – ResApp Health Limited (ASX:RAP) (**ResApp**), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, provides the following update in relation to the revised scheme of arrangement (**Revised Scheme**) pursuant to which Pfizer Australia Holdings Pty Limited (**Pfizer**) would acquire 100% of ResApp's issued shares¹.

Draft Scheme Booklet

ResApp confirms that the draft Scheme Booklet, including a copy of the draft independent expert report prepared by BDO Corporate Finance (WA) Pty Ltd, has now been lodged with the Australian Securities & Investments Commission (**ASIC**) for review. The ASIC review period is expected to be up to 14 days from submission, however can be extended at ASIC's discretion.

Despatch of Scheme Booklet and Scheme Meeting

Following completion of the ASIC review period, and assuming that the Supreme Court of New South Wales makes orders convening a ResApp shareholder meeting to consider and, if thought fit, approve the Revised Scheme (**Scheme Meeting**), and assuming also that the Scheme Booklet has been registered by ASIC, the Scheme Booklet will be publicly released via separate ASX announcement and despatched to shareholders.

Despatch of the Scheme Booklet is expected to occur in mid-July 2022 with the Scheme Meeting expected to be held in mid-August 2022. Shareholders will be able to attend the Scheme Meeting either in person or virtually. Details of the date, time and location of the Scheme Meeting will be confirmed once available.

No Waiver of Qualifying Confirmatory Data Readout Condition

ResApp has received confirmation from Pfizer that it will not waive the Qualifying Confirmatory Data Condition, confirming the Scheme Consideration of A\$0.146 per ResApp share in cash, representing an equity value of A\$127 million.

Directors Recommendation

The Directors of ResApp unanimously recommend that ResApp shareholders vote in favour of the Revised Scheme at the Scheme Meeting, in the absence of a superior proposal and subject to

¹ ASX Announcement 14 June 2022



the Independent Expert concluding in the final Independent Expert's Report (and continuing to conclude) that the Revised Scheme is in the best interests of ResApp shareholders.

Subject to those same qualifications, each member of the ResApp Board intends to vote, or cause to be voted, all ResApp shares held or controlled by them in favour of the Revised Scheme. Since the SID was announced on 11 April 2022, no party has engaged with ResApp with regard to evaluating or providing a competing proposal.

The Revised Scheme provides the opportunity for all ResApp shareholders to realise an attractive cash price for all their ResApp shares and avoid the risks associated with the execution of ResApp's long term strategy.

Further Information

If you require further information or have questions in relation to the Revised Scheme, please contact the ResApp Shareholder Information Line on 1300 620 649 (within Australia) or +613 9415 4326 (outside Australia), Monday to Friday between 8:30am and 5:00pm (AEST).

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.